GlassScriptPhysician profile
David Curt Chaffin
NPI 1235178377
$4,995.27
in general payments reported to CMS, 2019-2025
36 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $473 · 2021: $142 · 2022: $573 · 2023: $622 · 2024: $976 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,234.48 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $909.90 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $663.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $386.61 | 2019-2024 | Shingrix, Arexvy, Nucala |
| Novartis Pharmaceuticals Corporation | $248.73 | 2019-2025 | |
| Csl Behring | $230.06 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $184.88 | 2020-2025 | Takhzyro, Gattex, Hyqvia |
| Grifols USA, LLC | $166.84 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $113.85 | 2019-2022 | |
| Pfizer INC. | $106.78 | 2020-2025 | |
| Octapharma USA, INC. | $83.61 | 2022-2024 | Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.42 | 2019-2021 | |
| Kaleo, INC. | $69.36 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $57.59 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $44.80 | 2023-2025 | Orladeyo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $37.03 | 2019-2020 | |
| Shire North American Group INC | $36.16 | 2019 | |
| Pharming Healthcare, INC. | $33.70 | 2025 | Ruconest |
| Amgen INC. | $24.79 | 2022 | |
| Alk-Abello, INC | $24.70 | 2019 | |
| Optinose US, INC. | $22.93 | 2024 | |
| Lilly USA, LLC | $22.37 | 2024 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $21.83 | 2025 | Dawnzera |
| Incyte Corporation | $19.56 | 2022 | |
| Abbvie INC. | $19.38 | 2024 | |
| Merck Sharp & Dohme LLC | $18.11 | 2023 | |
| Cycle Pharmaceuticals INC | $17.59 | 2025 | Sajazir |
| Adma Biomanufacturing LLC | $16.43 | 2021 | |
| Covis Pharma Gmbh | $16.07 | 2019 | |
| Boston Scientific Corporation | $15.45 | 2021 | |
| Dexcom, INC. | $15.07 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $13.49 | 2021 | |
| Mylan Specialty L.P. | $13.18 | 2022 | |
| Hikma Pharmaceuticals USA | $12.99 | 2023 | Ryaltris |
| Mylan Pharmaceuticals INC. | $11.34 | 2019 | |
| Organon LLC | $6.24 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chaffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.